Regulatory Approval Healthcare & Pharmaceuticals News Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN 18 July 202617 July 2026 Regulatory Intelligence Desk
Regulatory Approval Healthcare & Pharmaceuticals News LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C 17 July 202617 July 2026 Regulatory Intelligence Desk
Merger & Acquisitions Business Healthcare & Pharmaceuticals GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline 16 July 202616 July 2026 BiotechReality Business Intelligence Desk
Business Healthcare & Pharmaceuticals News Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook 15 July 202616 July 2026 BiotechReality Business Intelligence Desk
Regulatory Approval Healthcare & Pharmaceuticals News Oncology Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment 15 July 202615 July 2026 Regulatory Intelligence Desk
Merger & Acquisitions Healthcare & Pharmaceuticals News Oncology AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement 14 July 202615 July 2026 BiotechReality Business Intelligence Desk